This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sage Therapeutics’s 8K filing here.
About Sage Therapeutics
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
See Also
- Five stocks we like better than Sage Therapeutics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Battle of the Retailers: Who Comes Out on Top?
- How to Use the MarketBeat Stock Screener
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- MarketBeat Week in Review – 10/28 – 11/1
